GPC3 CAR-T-CD39-VHH-PD-L1-ScFv

N/A

Report date: 2026/04/22 20:01:10

Base Information

Drug NameGPC3 CAR-T-CD39-VHH-PD-L1-ScFv
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)
Mechanisms of ActionAnti-Glypican-3Anti-Programmed death-ligand 1Anti-Ectonucleoside triphosphate diphosphohydrolase 1
TargetsGlypican-3Programmed death-ligand 1Ectonucleoside triphosphate diphosphohydrolase 1
Therapy Area/IndicationsLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co LtdGuangzhou First People'S Hospital
Inactive CompaniesN/A
Active IndicationsLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A